Stefan Sillau
Concepts (416)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Parkinson Disease | 20 | 2024 | 334 | 2.460 |
Why?
| Palliative Care | 12 | 2024 | 630 | 0.990 |
Why?
| Multiple Sclerosis | 7 | 2023 | 384 | 0.930 |
Why?
| Caregivers | 9 | 2024 | 707 | 0.790 |
Why?
| Seizures | 8 | 2023 | 345 | 0.720 |
Why?
| Quality of Life | 15 | 2024 | 2355 | 0.710 |
Why?
| Alzheimer Disease | 5 | 2024 | 512 | 0.630 |
Why?
| Epilepsy | 4 | 2023 | 290 | 0.590 |
Why?
| Drug Resistant Epilepsy | 3 | 2023 | 48 | 0.590 |
Why?
| Natalizumab | 4 | 2021 | 46 | 0.560 |
Why?
| Parkinsonian Disorders | 3 | 2020 | 29 | 0.520 |
Why?
| Fingolimod Hydrochloride | 3 | 2020 | 30 | 0.510 |
Why?
| Humans | 93 | 2024 | 118251 | 0.440 |
Why?
| Immunologic Factors | 3 | 2020 | 224 | 0.440 |
Why?
| Atherosclerosis | 4 | 2019 | 345 | 0.420 |
Why?
| Ambulatory Care | 3 | 2020 | 480 | 0.410 |
Why?
| Diabetic Neuropathies | 2 | 2023 | 78 | 0.400 |
Why?
| Charcot-Marie-Tooth Disease | 2 | 2022 | 19 | 0.400 |
Why?
| Sinusitis | 3 | 2021 | 175 | 0.380 |
Why?
| Chagas Disease | 2 | 2021 | 34 | 0.380 |
Why?
| Music Therapy | 2 | 2021 | 22 | 0.370 |
Why?
| Middle Aged | 37 | 2021 | 27510 | 0.350 |
Why?
| Male | 53 | 2024 | 57474 | 0.350 |
Why?
| Aged | 31 | 2024 | 19594 | 0.350 |
Why?
| Stroke, Lacunar | 2 | 2019 | 4 | 0.340 |
Why?
| Torticollis | 2 | 2019 | 12 | 0.340 |
Why?
| Retrospective Studies | 27 | 2024 | 12929 | 0.340 |
Why?
| Rituximab | 2 | 2020 | 153 | 0.330 |
Why?
| Multiple Sclerosis, Relapsing-Remitting | 2 | 2020 | 68 | 0.330 |
Why?
| Meningitis, Cryptococcal | 2 | 2019 | 28 | 0.330 |
Why?
| Dystonic Disorders | 2 | 2019 | 17 | 0.330 |
Why?
| Female | 53 | 2023 | 61261 | 0.330 |
Why?
| Cardiomyopathies | 2 | 2021 | 298 | 0.310 |
Why?
| Spirituality | 4 | 2021 | 65 | 0.300 |
Why?
| Medical Staff, Hospital | 2 | 2021 | 73 | 0.300 |
Why?
| Adult | 31 | 2023 | 31324 | 0.290 |
Why?
| Myelitis | 2 | 2018 | 88 | 0.290 |
Why?
| Sepsis | 2 | 2022 | 531 | 0.270 |
Why?
| Neurosurgical Procedures | 2 | 2017 | 164 | 0.270 |
Why?
| Adaptation, Psychological | 5 | 2020 | 545 | 0.260 |
Why?
| Cognition | 5 | 2023 | 1026 | 0.260 |
Why?
| Magnetic Resonance Imaging | 10 | 2024 | 3169 | 0.250 |
Why?
| Child Abuse | 2 | 2022 | 465 | 0.250 |
Why?
| Telemedicine | 2 | 2024 | 664 | 0.250 |
Why?
| Aged, 80 and over | 14 | 2021 | 6541 | 0.250 |
Why?
| Nasal Polyps | 2 | 2016 | 49 | 0.250 |
Why?
| Cerebral Amyloid Angiopathy | 1 | 2024 | 10 | 0.240 |
Why?
| Patient Care Team | 3 | 2019 | 521 | 0.240 |
Why?
| Cost of Illness | 3 | 2021 | 255 | 0.240 |
Why?
| Inpatients | 3 | 2021 | 387 | 0.240 |
Why?
| Dimethyl Fumarate | 2 | 2020 | 10 | 0.230 |
Why?
| Cognition Disorders | 2 | 2018 | 528 | 0.230 |
Why?
| Severity of Illness Index | 8 | 2020 | 2659 | 0.220 |
Why?
| Cannabidiol | 1 | 2023 | 53 | 0.210 |
Why?
| Apolipoprotein E4 | 1 | 2022 | 37 | 0.210 |
Why?
| Frontotemporal Dementia | 1 | 2022 | 31 | 0.210 |
Why?
| Conversion Disorder | 1 | 2022 | 10 | 0.210 |
Why?
| Sleep | 3 | 2021 | 650 | 0.210 |
Why?
| Vagus Nerve Stimulation | 1 | 2022 | 24 | 0.210 |
Why?
| Epilepsies, Partial | 1 | 2022 | 28 | 0.210 |
Why?
| Memory Consolidation | 1 | 2021 | 11 | 0.200 |
Why?
| Chagas Cardiomyopathy | 1 | 2021 | 21 | 0.200 |
Why?
| Motor Disorders | 1 | 2021 | 16 | 0.200 |
Why?
| Cross-Sectional Studies | 10 | 2021 | 4521 | 0.200 |
Why?
| Risk Assessment | 6 | 2023 | 3043 | 0.200 |
Why?
| Dermatitis, Seborrheic | 1 | 2020 | 4 | 0.200 |
Why?
| Disease Progression | 4 | 2022 | 2477 | 0.190 |
Why?
| Intellectual Disability | 1 | 2022 | 136 | 0.190 |
Why?
| Colorado | 11 | 2021 | 4178 | 0.190 |
Why?
| Hospice and Palliative Care Nursing | 1 | 2022 | 68 | 0.190 |
Why?
| Attitude of Health Personnel | 2 | 2021 | 990 | 0.190 |
Why?
| Terminal Care | 1 | 2023 | 187 | 0.190 |
Why?
| Basal Ganglia Diseases | 1 | 2020 | 7 | 0.190 |
Why?
| Vitamin D | 2 | 2015 | 352 | 0.190 |
Why?
| Self Report | 3 | 2022 | 698 | 0.190 |
Why?
| Treatment Outcome | 12 | 2022 | 9319 | 0.190 |
Why?
| Multiple Sclerosis, Chronic Progressive | 1 | 2020 | 25 | 0.180 |
Why?
| Tumor Necrosis Factor-alpha | 2 | 2022 | 1159 | 0.180 |
Why?
| Young Adult | 14 | 2022 | 10731 | 0.180 |
Why?
| Electronic Health Records | 2 | 2021 | 809 | 0.180 |
Why?
| Cytokines | 3 | 2022 | 1880 | 0.180 |
Why?
| Sphenoid Bone | 2 | 2016 | 16 | 0.180 |
Why?
| Neurovascular Coupling | 1 | 2019 | 7 | 0.180 |
Why?
| Interferon-gamma | 1 | 2023 | 735 | 0.180 |
Why?
| Diabetes Mellitus, Type 2 | 3 | 2023 | 2159 | 0.180 |
Why?
| Shock, Septic | 1 | 2021 | 187 | 0.170 |
Why?
| Down Syndrome | 2 | 2022 | 328 | 0.170 |
Why?
| Radiotherapy, Adjuvant | 2 | 2016 | 189 | 0.170 |
Why?
| Behavioral Symptoms | 1 | 2019 | 43 | 0.170 |
Why?
| Glatiramer Acetate | 1 | 2019 | 20 | 0.170 |
Why?
| Cannabinoids | 1 | 2020 | 115 | 0.170 |
Why?
| Disabled Persons | 1 | 2021 | 147 | 0.170 |
Why?
| Critical Care Outcomes | 1 | 2018 | 12 | 0.170 |
Why?
| Psychotherapy, Group | 1 | 2019 | 61 | 0.170 |
Why?
| Cognitive Dysfunction | 1 | 2023 | 301 | 0.170 |
Why?
| Streptococcal Infections | 1 | 2021 | 141 | 0.170 |
Why?
| Electroencephalography | 4 | 2022 | 387 | 0.170 |
Why?
| Cohort Studies | 8 | 2021 | 5078 | 0.170 |
Why?
| Psychometrics | 2 | 2019 | 625 | 0.170 |
Why?
| Diet, Ketogenic | 1 | 2018 | 32 | 0.170 |
Why?
| Blepharospasm | 1 | 2018 | 7 | 0.160 |
Why?
| Restless Legs Syndrome | 1 | 2018 | 18 | 0.160 |
Why?
| Fluoxetine | 1 | 2018 | 47 | 0.160 |
Why?
| Proxy | 1 | 2018 | 22 | 0.160 |
Why?
| Basal Ganglia | 1 | 2018 | 44 | 0.160 |
Why?
| Aftercare | 1 | 2020 | 194 | 0.160 |
Why?
| Subthalamic Nucleus | 1 | 2018 | 37 | 0.160 |
Why?
| Clinical Laboratory Techniques | 1 | 2018 | 89 | 0.160 |
Why?
| Brain | 5 | 2022 | 2481 | 0.160 |
Why?
| Immunosuppressive Agents | 2 | 2019 | 682 | 0.160 |
Why?
| Central Nervous System Viral Diseases | 1 | 2018 | 63 | 0.160 |
Why?
| Nutrition Surveys | 1 | 2019 | 232 | 0.150 |
Why?
| Autism Spectrum Disorder | 1 | 2022 | 324 | 0.150 |
Why?
| Neurology | 1 | 2019 | 94 | 0.150 |
Why?
| Hypoxia-Ischemia, Brain | 1 | 2017 | 26 | 0.150 |
Why?
| Transcranial Magnetic Stimulation | 1 | 2017 | 43 | 0.150 |
Why?
| Ambulatory Care Facilities | 1 | 2019 | 216 | 0.150 |
Why?
| Deep Brain Stimulation | 1 | 2018 | 72 | 0.150 |
Why?
| Neuromuscular Diseases | 1 | 2018 | 90 | 0.150 |
Why?
| Prevalence | 6 | 2022 | 2321 | 0.150 |
Why?
| Cranial Nerve Diseases | 1 | 2017 | 42 | 0.150 |
Why?
| Follow-Up Studies | 7 | 2020 | 4574 | 0.150 |
Why?
| Movement Disorders | 1 | 2017 | 45 | 0.150 |
Why?
| Interprofessional Relations | 1 | 2019 | 260 | 0.150 |
Why?
| Immunoglobulin G | 1 | 2021 | 785 | 0.150 |
Why?
| Medical Marijuana | 1 | 2018 | 102 | 0.140 |
Why?
| Orbital Diseases | 1 | 2016 | 26 | 0.140 |
Why?
| Giant Cell Tumor of Bone | 1 | 2016 | 6 | 0.140 |
Why?
| Muscular Diseases | 1 | 2017 | 107 | 0.140 |
Why?
| Cannabis | 1 | 2023 | 381 | 0.140 |
Why?
| Atrophy | 3 | 2024 | 164 | 0.140 |
Why?
| Adolescent | 13 | 2023 | 18364 | 0.140 |
Why?
| Dementia | 1 | 2019 | 207 | 0.140 |
Why?
| Cerebellum | 1 | 2018 | 203 | 0.140 |
Why?
| Skull Base Neoplasms | 1 | 2016 | 29 | 0.140 |
Why?
| Child | 13 | 2022 | 19033 | 0.140 |
Why?
| Craniocerebral Trauma | 1 | 2017 | 146 | 0.140 |
Why?
| Models, Theoretical | 1 | 2020 | 554 | 0.140 |
Why?
| Meningioma | 1 | 2016 | 82 | 0.130 |
Why?
| Radiotherapy, Intensity-Modulated | 1 | 2016 | 128 | 0.130 |
Why?
| T-Lymphocytes | 1 | 2023 | 1770 | 0.130 |
Why?
| Meningeal Neoplasms | 1 | 2016 | 90 | 0.130 |
Why?
| Burnout, Professional | 1 | 2021 | 322 | 0.130 |
Why?
| Longitudinal Studies | 3 | 2022 | 2491 | 0.130 |
Why?
| Risk Factors | 9 | 2019 | 8958 | 0.130 |
Why?
| Marijuana Smoking | 1 | 2018 | 220 | 0.130 |
Why?
| Regression Analysis | 2 | 2018 | 984 | 0.130 |
Why?
| Hemodynamics | 1 | 2019 | 1002 | 0.130 |
Why?
| Craniofacial Abnormalities | 1 | 2015 | 59 | 0.130 |
Why?
| Education, Medical, Graduate | 1 | 2019 | 399 | 0.130 |
Why?
| Motor Activity | 1 | 2019 | 664 | 0.120 |
Why?
| Rhinitis | 1 | 2016 | 129 | 0.120 |
Why?
| Data Collection | 2 | 2022 | 652 | 0.120 |
Why?
| Retinopathy of Prematurity | 1 | 2016 | 111 | 0.120 |
Why?
| Stroke | 2 | 2020 | 1046 | 0.120 |
Why?
| Aspirin | 2 | 2016 | 334 | 0.120 |
Why?
| Patient Readmission | 1 | 2020 | 631 | 0.120 |
Why?
| Physicians | 1 | 2023 | 792 | 0.120 |
Why?
| Neonatal Screening | 1 | 2016 | 151 | 0.120 |
Why?
| Urolithiasis | 1 | 2014 | 8 | 0.120 |
Why?
| Ureteroscopy | 1 | 2014 | 16 | 0.120 |
Why?
| Anxiety Disorders | 1 | 2017 | 310 | 0.120 |
Why?
| Neoplasm Recurrence, Local | 2 | 2016 | 895 | 0.120 |
Why?
| Vitamin D Deficiency | 2 | 2015 | 161 | 0.120 |
Why?
| Eosinophilia | 1 | 2016 | 185 | 0.120 |
Why?
| Depressive Disorder | 1 | 2017 | 332 | 0.120 |
Why?
| Neuropsychological Tests | 1 | 2018 | 1027 | 0.120 |
Why?
| Behavioral Medicine | 1 | 2014 | 42 | 0.120 |
Why?
| Extremities | 1 | 2014 | 112 | 0.120 |
Why?
| Chronic Disease | 2 | 2016 | 1630 | 0.120 |
Why?
| Tonsillectomy | 1 | 2015 | 80 | 0.120 |
Why?
| Nervous System Diseases | 1 | 2016 | 261 | 0.120 |
Why?
| Patient-Centered Care | 1 | 2019 | 493 | 0.120 |
Why?
| Rural Health Services | 1 | 2014 | 93 | 0.120 |
Why?
| Mental Disorders | 1 | 2021 | 935 | 0.120 |
Why?
| Prognosis | 4 | 2023 | 3424 | 0.110 |
Why?
| Pulmonary Ventilation | 1 | 2013 | 71 | 0.110 |
Why?
| Refugees | 1 | 2014 | 56 | 0.110 |
Why?
| Demography | 1 | 2014 | 273 | 0.110 |
Why?
| Airway Obstruction | 1 | 2015 | 167 | 0.110 |
Why?
| Primary Prevention | 1 | 2015 | 183 | 0.110 |
Why?
| Antiviral Agents | 1 | 2018 | 653 | 0.110 |
Why?
| Tomography, X-Ray Computed | 4 | 2016 | 2433 | 0.110 |
Why?
| Birth Weight | 1 | 2016 | 463 | 0.110 |
Why?
| Incidence | 4 | 2022 | 2413 | 0.110 |
Why?
| Coronary Vessels | 1 | 2014 | 233 | 0.110 |
Why?
| Weight Gain | 1 | 2016 | 485 | 0.110 |
Why?
| Movement | 1 | 2014 | 248 | 0.110 |
Why?
| Teaching Rounds | 1 | 2013 | 60 | 0.110 |
Why?
| Curriculum | 1 | 2019 | 908 | 0.110 |
Why?
| Coronary Disease | 1 | 2014 | 355 | 0.100 |
Why?
| Depression | 1 | 2020 | 1133 | 0.100 |
Why?
| Tissue Donors | 1 | 2014 | 334 | 0.100 |
Why?
| Calcinosis | 1 | 2014 | 282 | 0.100 |
Why?
| Sleep Apnea, Obstructive | 1 | 2015 | 232 | 0.100 |
Why?
| Delivery of Health Care, Integrated | 1 | 2014 | 230 | 0.100 |
Why?
| Environmental Monitoring | 1 | 2013 | 295 | 0.100 |
Why?
| Internal Medicine | 1 | 2013 | 215 | 0.100 |
Why?
| Reproducibility of Results | 4 | 2022 | 2855 | 0.100 |
Why?
| Surveys and Questionnaires | 6 | 2019 | 4684 | 0.100 |
Why?
| Interpersonal Relations | 1 | 2014 | 342 | 0.100 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2015 | 387 | 0.090 |
Why?
| Tissue and Organ Procurement | 1 | 2014 | 247 | 0.090 |
Why?
| Family | 1 | 2014 | 578 | 0.090 |
Why?
| Amyloid beta-Peptides | 2 | 2023 | 200 | 0.090 |
Why?
| Polysomnography | 3 | 2015 | 156 | 0.090 |
Why?
| Patient Outcome Assessment | 2 | 2023 | 123 | 0.090 |
Why?
| United States | 7 | 2022 | 12488 | 0.090 |
Why?
| Obesity | 2 | 2021 | 2715 | 0.090 |
Why?
| Cross Infection | 1 | 2012 | 204 | 0.090 |
Why?
| Time Factors | 5 | 2020 | 6368 | 0.090 |
Why?
| Case-Control Studies | 3 | 2023 | 3156 | 0.090 |
Why?
| Postoperative Complications | 2 | 2017 | 2230 | 0.090 |
Why?
| Models, Statistical | 1 | 2013 | 633 | 0.090 |
Why?
| Brain Neoplasms | 1 | 2017 | 1019 | 0.090 |
Why?
| Phenotype | 1 | 2017 | 2937 | 0.080 |
Why?
| Internship and Residency | 1 | 2019 | 1005 | 0.080 |
Why?
| Cardiac Surgical Procedures | 1 | 2013 | 458 | 0.080 |
Why?
| Health Status | 1 | 2014 | 723 | 0.080 |
Why?
| Coronary Artery Disease | 1 | 2015 | 648 | 0.080 |
Why?
| Quality of Health Care | 1 | 2013 | 585 | 0.080 |
Why?
| Calcium | 1 | 2014 | 1151 | 0.080 |
Why?
| Prospective Studies | 5 | 2023 | 6443 | 0.080 |
Why?
| Intensive Care Units | 1 | 2012 | 633 | 0.080 |
Why?
| Muscle, Skeletal | 1 | 2017 | 1515 | 0.080 |
Why?
| Health Services Accessibility | 1 | 2014 | 776 | 0.080 |
Why?
| Blood Pressure | 1 | 2014 | 1656 | 0.080 |
Why?
| Length of Stay | 1 | 2012 | 1027 | 0.080 |
Why?
| Patient Participation | 2 | 2022 | 368 | 0.070 |
Why?
| Internet | 1 | 2011 | 602 | 0.070 |
Why?
| Lung Diseases | 1 | 2013 | 709 | 0.070 |
Why?
| Double-Blind Method | 2 | 2023 | 1683 | 0.070 |
Why?
| Heart Defects, Congenital | 1 | 2013 | 700 | 0.070 |
Why?
| Critical Illness | 1 | 2012 | 661 | 0.070 |
Why?
| Recurrence | 2 | 2020 | 971 | 0.070 |
Why?
| Feasibility Studies | 2 | 2019 | 746 | 0.070 |
Why?
| Asthma | 3 | 2016 | 2143 | 0.070 |
Why?
| Influenza, Human | 1 | 2011 | 553 | 0.070 |
Why?
| Hypertension | 1 | 2014 | 1199 | 0.070 |
Why?
| Survival Analysis | 2 | 2019 | 1262 | 0.070 |
Why?
| Health Knowledge, Attitudes, Practice | 1 | 2014 | 1183 | 0.070 |
Why?
| Randomized Controlled Trials as Topic | 2 | 2021 | 1237 | 0.060 |
Why?
| Child, Preschool | 4 | 2020 | 9448 | 0.060 |
Why?
| Anxiety | 2 | 2021 | 845 | 0.060 |
Why?
| Research Design | 2 | 2021 | 961 | 0.060 |
Why?
| Sleep Wake Disorders | 2 | 2019 | 238 | 0.060 |
Why?
| Neurologists | 1 | 2024 | 19 | 0.060 |
Why?
| Primary Health Care | 1 | 2014 | 1539 | 0.060 |
Why?
| Amyloidogenic Proteins | 1 | 2023 | 10 | 0.060 |
Why?
| Comorbidity | 2 | 2021 | 1516 | 0.060 |
Why?
| Pandemics | 2 | 2022 | 1338 | 0.060 |
Why?
| Intermediate Filaments | 1 | 2023 | 46 | 0.060 |
Why?
| Neurofilament Proteins | 1 | 2023 | 33 | 0.060 |
Why?
| Vaccination | 1 | 2011 | 1218 | 0.060 |
Why?
| Sensitivity and Specificity | 2 | 2020 | 1787 | 0.060 |
Why?
| Cerebral Hemorrhage | 1 | 2024 | 100 | 0.060 |
Why?
| tau Proteins | 1 | 2023 | 78 | 0.060 |
Why?
| Myelin P0 Protein | 1 | 2022 | 7 | 0.060 |
Why?
| Biomarkers | 2 | 2023 | 3567 | 0.060 |
Why?
| Imipramine | 1 | 2022 | 14 | 0.050 |
Why?
| Hypertension, Pulmonary | 1 | 2013 | 1784 | 0.050 |
Why?
| Dronabinol | 1 | 2023 | 120 | 0.050 |
Why?
| Infusions, Intravenous | 1 | 2023 | 379 | 0.050 |
Why?
| Pain | 2 | 2018 | 736 | 0.050 |
Why?
| Facial Expression | 1 | 2022 | 62 | 0.050 |
Why?
| Healthy Volunteers | 1 | 2022 | 194 | 0.050 |
Why?
| Polymerization | 1 | 2022 | 129 | 0.050 |
Why?
| Vagus Nerve | 1 | 2022 | 80 | 0.050 |
Why?
| Predictive Value of Tests | 2 | 2019 | 1857 | 0.050 |
Why?
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2022 | 142 | 0.050 |
Why?
| Catalysis | 1 | 2022 | 295 | 0.050 |
Why?
| Reference Standards | 1 | 2022 | 174 | 0.050 |
Why?
| Streptococcus anginosus | 1 | 2021 | 8 | 0.050 |
Why?
| Inflammation | 2 | 2022 | 2545 | 0.050 |
Why?
| Oncology Service, Hospital | 1 | 2021 | 14 | 0.050 |
Why?
| Interneurons | 1 | 2022 | 103 | 0.050 |
Why?
| Lung | 1 | 2013 | 3623 | 0.050 |
Why?
| Outpatients | 1 | 2024 | 324 | 0.050 |
Why?
| Meta-Analysis as Topic | 1 | 2021 | 164 | 0.050 |
Why?
| Immune System | 1 | 2022 | 181 | 0.050 |
Why?
| Hospitals, University | 1 | 2021 | 172 | 0.050 |
Why?
| Longevity | 1 | 2021 | 150 | 0.050 |
Why?
| Reaction Time | 1 | 2022 | 390 | 0.050 |
Why?
| Serine | 1 | 2021 | 137 | 0.050 |
Why?
| Astrocytes | 1 | 2022 | 176 | 0.050 |
Why?
| Medical Informatics | 1 | 2021 | 97 | 0.050 |
Why?
| Efficiency, Organizational | 1 | 2021 | 126 | 0.050 |
Why?
| Antibodies, Viral | 1 | 2023 | 538 | 0.050 |
Why?
| Electrodes, Implanted | 1 | 2020 | 97 | 0.040 |
Why?
| Multiple System Atrophy | 1 | 2019 | 4 | 0.040 |
Why?
| Infant | 3 | 2018 | 8254 | 0.040 |
Why?
| Supranuclear Palsy, Progressive | 1 | 2019 | 6 | 0.040 |
Why?
| Monitoring, Physiologic | 1 | 2022 | 268 | 0.040 |
Why?
| Age Distribution | 1 | 2020 | 358 | 0.040 |
Why?
| Sex Distribution | 1 | 2020 | 347 | 0.040 |
Why?
| Lewy Body Disease | 1 | 2019 | 15 | 0.040 |
Why?
| Developmental Disabilities | 1 | 2022 | 245 | 0.040 |
Why?
| Income | 1 | 2020 | 173 | 0.040 |
Why?
| Peptide Fragments | 1 | 2023 | 700 | 0.040 |
Why?
| Maintenance Chemotherapy | 1 | 2019 | 23 | 0.040 |
Why?
| Music | 1 | 2019 | 37 | 0.040 |
Why?
| Qualitative Research | 1 | 2024 | 952 | 0.040 |
Why?
| Pragmatic Clinical Trials as Topic | 1 | 2019 | 48 | 0.040 |
Why?
| Induction Chemotherapy | 1 | 2019 | 59 | 0.040 |
Why?
| Stroke Volume | 1 | 2021 | 513 | 0.040 |
Why?
| Symptom Assessment | 1 | 2019 | 123 | 0.040 |
Why?
| Gait | 1 | 2021 | 253 | 0.040 |
Why?
| Logistic Models | 2 | 2014 | 1896 | 0.040 |
Why?
| Carnitine | 1 | 2018 | 65 | 0.040 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2023 | 665 | 0.040 |
Why?
| Tandem Mass Spectrometry | 1 | 2021 | 418 | 0.040 |
Why?
| Administration, Oral | 1 | 2020 | 753 | 0.040 |
Why?
| Ventricular Function, Left | 1 | 2021 | 468 | 0.040 |
Why?
| B-Lymphocytes | 1 | 2023 | 767 | 0.040 |
Why?
| Demyelinating Diseases | 1 | 2019 | 79 | 0.040 |
Why?
| Phosphorus | 1 | 2018 | 84 | 0.040 |
Why?
| Age of Onset | 1 | 2019 | 465 | 0.040 |
Why?
| Muscle Spasticity | 1 | 2018 | 53 | 0.040 |
Why?
| Comparative Effectiveness Research | 1 | 2019 | 131 | 0.040 |
Why?
| Arrhythmias, Cardiac | 1 | 2020 | 277 | 0.040 |
Why?
| Health Services | 1 | 2019 | 109 | 0.040 |
Why?
| Diffusion Tensor Imaging | 1 | 2018 | 73 | 0.040 |
Why?
| Neural Pathways | 1 | 2019 | 277 | 0.040 |
Why?
| Gadolinium | 1 | 2018 | 78 | 0.040 |
Why?
| Emotions | 1 | 2022 | 494 | 0.040 |
Why?
| Hippocampus | 1 | 2022 | 735 | 0.040 |
Why?
| Neural Conduction | 1 | 2017 | 81 | 0.040 |
Why?
| ROC Curve | 1 | 2018 | 470 | 0.040 |
Why?
| Sex Characteristics | 1 | 2022 | 667 | 0.040 |
Why?
| Disability Evaluation | 1 | 2019 | 278 | 0.040 |
Why?
| Exophthalmos | 1 | 2016 | 19 | 0.040 |
Why?
| Neuroimaging | 1 | 2019 | 256 | 0.040 |
Why?
| Temporomandibular Joint | 1 | 2016 | 12 | 0.040 |
Why?
| Frontal Bone | 1 | 2016 | 13 | 0.040 |
Why?
| Cranial Fossa, Middle | 1 | 2016 | 7 | 0.040 |
Why?
| Interviews as Topic | 1 | 2019 | 593 | 0.040 |
Why?
| Occipital Bone | 1 | 2016 | 20 | 0.040 |
Why?
| Sex Factors | 1 | 2022 | 1765 | 0.040 |
Why?
| Brain Ischemia | 1 | 2020 | 309 | 0.030 |
Why?
| Intraoperative Complications | 1 | 2017 | 133 | 0.030 |
Why?
| Temporal Bone | 1 | 2016 | 43 | 0.030 |
Why?
| Self Efficacy | 1 | 2019 | 347 | 0.030 |
Why?
| Neoplasm Grading | 1 | 2016 | 257 | 0.030 |
Why?
| Brain Mapping | 1 | 2019 | 530 | 0.030 |
Why?
| Drug Administration Schedule | 1 | 2018 | 734 | 0.030 |
Why?
| Neoplasm, Residual | 1 | 2016 | 103 | 0.030 |
Why?
| Activities of Daily Living | 1 | 2018 | 353 | 0.030 |
Why?
| Electromyography | 1 | 2017 | 326 | 0.030 |
Why?
| Anticonvulsants | 1 | 2017 | 184 | 0.030 |
Why?
| Sleep Stages | 1 | 2015 | 60 | 0.030 |
Why?
| Contrast Media | 1 | 2018 | 373 | 0.030 |
Why?
| Patient Reported Outcome Measures | 1 | 2017 | 251 | 0.030 |
Why?
| Actigraphy | 1 | 2015 | 80 | 0.030 |
Why?
| Psychiatric Status Rating Scales | 1 | 2017 | 499 | 0.030 |
Why?
| Drug Hypersensitivity | 1 | 2016 | 85 | 0.030 |
Why?
| Pilot Projects | 1 | 2019 | 1405 | 0.030 |
Why?
| Adenoidectomy | 1 | 2015 | 63 | 0.030 |
Why?
| Thinness | 1 | 2015 | 91 | 0.030 |
Why?
| Sleep Apnea Syndromes | 1 | 2015 | 80 | 0.030 |
Why?
| Infant, Newborn | 2 | 2016 | 5230 | 0.030 |
Why?
| Age Factors | 1 | 2022 | 2990 | 0.030 |
Why?
| San Francisco | 1 | 2014 | 57 | 0.030 |
Why?
| Sampling Studies | 1 | 2014 | 91 | 0.030 |
Why?
| Sternotomy | 1 | 2013 | 11 | 0.030 |
Why?
| False Positive Reactions | 1 | 2014 | 115 | 0.030 |
Why?
| Lithotripsy | 1 | 2014 | 37 | 0.030 |
Why?
| Combined Modality Therapy | 1 | 2016 | 1163 | 0.030 |
Why?
| Physician-Nurse Relations | 1 | 2013 | 15 | 0.030 |
Why?
| Pulmonary Gas Exchange | 1 | 2013 | 117 | 0.030 |
Why?
| Biopsy | 1 | 2017 | 1078 | 0.030 |
Why?
| Leukotriene E4 | 1 | 2013 | 28 | 0.030 |
Why?
| Critical Care | 1 | 2017 | 488 | 0.030 |
Why?
| Odds Ratio | 1 | 2016 | 993 | 0.030 |
Why?
| Thoracotomy | 1 | 2013 | 83 | 0.030 |
Why?
| Gestational Age | 1 | 2016 | 765 | 0.030 |
Why?
| Patient Acceptance of Health Care | 1 | 2019 | 683 | 0.030 |
Why?
| Monte Carlo Method | 1 | 2013 | 146 | 0.030 |
Why?
| Paranasal Sinuses | 1 | 2013 | 64 | 0.030 |
Why?
| Hospitals, Teaching | 1 | 2013 | 104 | 0.030 |
Why?
| Spirometry | 1 | 2013 | 262 | 0.030 |
Why?
| Drug Resistance | 1 | 2013 | 167 | 0.030 |
Why?
| Vital Capacity | 1 | 2013 | 260 | 0.030 |
Why?
| Olfaction Disorders | 1 | 2013 | 47 | 0.030 |
Why?
| Linear Models | 1 | 2015 | 817 | 0.030 |
Why?
| Diabetic Angiopathies | 1 | 2015 | 261 | 0.030 |
Why?
| Disease Models, Animal | 1 | 2022 | 3676 | 0.030 |
Why?
| Paper | 1 | 2011 | 9 | 0.030 |
Why?
| Coronary Angiography | 1 | 2014 | 311 | 0.030 |
Why?
| Disease-Free Survival | 1 | 2014 | 649 | 0.030 |
Why?
| Forced Expiratory Volume | 1 | 2013 | 520 | 0.030 |
Why?
| Mutation | 1 | 2022 | 3435 | 0.030 |
Why?
| Health Care Surveys | 1 | 2014 | 544 | 0.030 |
Why?
| Personnel, Hospital | 1 | 2011 | 23 | 0.030 |
Why?
| Premature Birth | 1 | 2015 | 284 | 0.030 |
Why?
| Particulate Matter | 1 | 2013 | 234 | 0.020 |
Why?
| Aging | 1 | 2021 | 1675 | 0.020 |
Why?
| Confidence Intervals | 1 | 2012 | 324 | 0.020 |
Why?
| Eosinophils | 1 | 2013 | 282 | 0.020 |
Why?
| Urban Population | 1 | 2014 | 408 | 0.020 |
Why?
| Oxygen Consumption | 1 | 2013 | 585 | 0.020 |
Why?
| Exercise Test | 1 | 2013 | 552 | 0.020 |
Why?
| Tobacco Smoke Pollution | 1 | 2013 | 231 | 0.020 |
Why?
| Patient Admission | 1 | 2012 | 177 | 0.020 |
Why?
| Cause of Death | 1 | 2012 | 379 | 0.020 |
Why?
| Socioeconomic Factors | 1 | 2014 | 1121 | 0.020 |
Why?
| Recovery of Function | 1 | 2013 | 603 | 0.020 |
Why?
| Computer Simulation | 1 | 2013 | 913 | 0.020 |
Why?
| Proportional Hazards Models | 1 | 2012 | 1124 | 0.020 |
Why?
| Algorithms | 1 | 2016 | 1522 | 0.020 |
Why?
| Models, Biological | 1 | 2016 | 1701 | 0.020 |
Why?
| Healthcare Disparities | 1 | 2014 | 494 | 0.020 |
Why?
| Practice Guidelines as Topic | 1 | 2015 | 1433 | 0.020 |
Why?
| Influenza Vaccines | 1 | 2011 | 501 | 0.020 |
Why?
| Patient Discharge | 1 | 2012 | 791 | 0.020 |
Why?
| Mice | 1 | 2022 | 15446 | 0.020 |
Why?
| Animals | 1 | 2022 | 33152 | 0.010 |
Why?
|
|
Sillau's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|